Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- PhRMA Prods Japan to Harness Power of RWD in Drug Development, Medical Care Evaluation
February 3, 2021
- JPMA, National Centers to Build Integrated Database for Drug Discovery; 1st Focus on Neurology/Psychiatry, Immune/Inflammation
January 26, 2021
- 3 Indicted Wholesalers Barred from JCHO/NHO Bids, but Can Sell Single-Channel Drugs to Ensure Access
January 26, 2021
- JPMA Exec Raps Off-Year Re-Pricing Plan, Says It Significantly Mars Predictability
January 22, 2021
- Generic Use Targets Should Be Set by City/Ward in Major Prefectures: Professor
January 14, 2021
- Yaz Generics to Carry Single Brand Name of DroEthi
January 13, 2021
- JPMA Chief Vows Renewed Efforts to Deliver COVID-19 Drugs, Vaccines as Japan Declares 2nd Emergency
January 12, 2021
- Japan Pharma Lobbies Shifting to Manabe/Okada Leadership? Their Abilities Will Be Tested as Industry Grapples with Thorny Issues
January 7, 2021
- 5% Discrepancy Line a Bad Surprise, FPMAJ Exec Says Drug Prices Will Now Go Down at Double Speed with Annual Re-Pricing
January 5, 2021
- First Time FPMAJ’s Supply Coordination Scheme Invoked for 13 APIs Tied to Kobayashi Kako
January 5, 2021
- Corporate Culture, Attitude of Management at Root of Kobayashi Kako Scandal: MHLW Official
January 5, 2021
- Tohoku Univ, JPMA, MICIN Launch Pilot Study on Wearable Data Collection
December 24, 2020
- National Hospital Organization to Switch from Kobayashi Kako Products after Itraconazole Mix-Up
December 22, 2020
- 3 Hospitals in Wakayama to Select Recommended Drugs after Mass Generic Recalls, De-Facto Regional Formulary
December 22, 2020
- 3 Indicted Wholesalers Now Barred from National Hospital Organization Bids, Others Following Suit
December 21, 2020
- 3 Pharma Groups Rap Off-Year Drug Re-Pricing Plan; Generic Industry Frets Impact on Stable Supplies
December 21, 2020
- AbbVie’s James Feliciano to Take Helm at PhRMA Japan in January
December 18, 2020
- Savings from Off-Year Re-Pricing Should Go Towards Physician Fees: JMA Chief
December 17, 2020
- Tokushukai Switching from Kobayashi Kako Products after Tainted Itraconazole Issue
December 16, 2020
- 3 Indicted Wholesalers Barred from JCHO Bids for 2 Years: Bid-Rigging Scandal
December 14, 2020
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…